Overall, the study indicates that the benefits of ADF may be from the suppression on mitochondrial complex II activity by decrease of SDHAF4 and that modulation of hepatic SDHAF4 level could be a possible approach for managing insulin sensitivity and related metabolic disorders. Here, INS is linked to metabolic disease.